Key points are not available for this paper at this time.
Tislelizumab was found to have a significantly improved and long-term clinical benefit in OS versus docetaxel in pretreated patients with advanced NSCLC, regardless of PD-L1 expression.
Zhou et al. (Thu,) studied this question.